Topics

Highly anticipated data for Novartis’ Zolgensma will boost the drug’s uptake despite controversies

05:13 EDT 26 Mar 2020 | Pharmaceutical Technology

On 24 March, Novartis announced new anticipated long-term positive data for its one-time infusion gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), that...
Read More...

The post Highly anticipated data for Novartis’ Zolgensma will boost the drug’s uptake despite controversies appeared first on Pharmaceutical Technology.

Original Article: Highly anticipated data for Novartis’ Zolgensma will boost the drug’s uptake despite controversies

NEXT ARTICLE

More From BioPortfolio on "Highly anticipated data for Novartis’ Zolgensma will boost the drug’s uptake despite controversies"

Quick Search

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...